

(19)  **Canadian
Intellectual Property
Office**

An Agency of
Industry Canada

**Office de la Propriété
Intellectuelle
du Canada**

Un organisme
d'Industrie Canada

(11) **CA 2 363 528**

(13) **A1**

(40) **19.05.2003**
(43) **19.05.2003**

(12)

(21) **2 363 528**

(51) Int. Cl. 7: **A61K 31/192, A61K 47/06,
A61K 9/20**

(22) **19.11.2001**

(71)

**MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER
HAFTUNG,
Frankfurter Strasse 250
D-64293, DARMSTADT, XX (DE).**

**GIAMBATTISTO, DAN F. (US).
AL-GHAZAWI, AHMAD (GB).
NUGURU, KALYAN S. (US).**

(74)

FETHERSTONHAUGH & CO.

(72)

(54) **PASTILLE A LIBERATION IMMEDIATE CONTENANT DU NAPROXEN SODIQUE**
(54) **IMMEDIATE RELEASE TABLET CONTAINING NAPROXEN SODIUM**

(57)

The present invention relates to a new tablet having an improved dissolution rate of Naproxen Sodium comprising Naproxen Sodium and spray-dried mannitol. The invention further relates to a method of manufacturing said tablet.



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2363528 A1 2003/05/19

(21) **2 363 528**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(22) Date de dépôt/Filing Date: 2001/11/19

(41) Mise à la disp. pub./Open to Public Insp.: 2003/05/19

(51) Cl.Int.⁷/Int.Cl.⁷ A61K 31/192, A61K 9/20, A61K 47/06

(71) Demandeur/Applicant:
MERCK PATENT GESELLSCHAFT MIT
BESCHRANKTER HAFTUNG, DE

(72) Inventeurs/Inventors:
AL-GHAZAWI, AHMAD, GB;
GIAMBATTISTO, DAN F., US;
NUGURU, KALYAN S., US

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : PASTILLE A LIBERATION IMMEDIATE CONTENANT DU NAPROXEN SODIQUE
(54) Title: IMMEDIATE RELEASE TABLET CONTAINING NAPROXEN SODIUM

(57) Abrégé/Abstract:

The present invention relates to a new tablet having an improved dissolution rate of Naproxen Sodium comprising Naproxen Sodium and spray-dried mannitol. The invention further relates to a method of manufacturing said tablet.

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>

OPIC • CIPO 191

OPIC



CIPO

ABSTRACT

The present invention relates to a new tablet having an improved dissolution rate of Naproxen Sodium comprising Naproxen Sodium and spray-dried mannitol. The invention further relates to a method of manufacturing said tablet.

I 01/312-Lg

Immediate release tablet containing Naproxen Sodium

The present invention is directed to a new tablet having improved dissolution rate of Naproxen Sodium and to a method of manufacturing of said formulation.

Naproxen Sodium is a well-known anti-inflammatory, analgesic, and antipyretic agent used in the symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, primary dysmenorrhea and for relief of mild to moderate pain. It has been approved in many countries around the world for almost two decades and has a very safe risk-benefit profile. In the United States it is sold, for example, under the trade name ALEVE[®] (distributed by Bayer Corporation, Consumer Care Division, Morristown, NJ) and as generic Naproxen Sodium tablets (distributed by Rite-Aid Corporation, Harrisburg, PA). The chemical name of Naproxen Sodium is (-)-6-methoxy- α -methyl-2-naphthaleneacetic acid, sodium salt.

Especially in case of using of naproxen tablets for the treatment of pain a fast onset of action is required and highly desired.

WO 98/35666 A1 describes tablets comprising naproxen nanoparticles having adsorbed on its surface a surface modifying agent and further excipients. Naproxen nanoparticles are obtained by wet grinding of naproxen together with the surface modifying agent, separating the surface modified particles obtained, spray drying and sieving. Accordingly, production of solid formulation is complicated and costly.

WO 00/13672 A1 assigned to the same company as WO 98/35666 A1 describes a solid nanoparticulate formulation obtained by compression of naproxene

I 01/312-Lg

- 2 -

nanoparticles having adsorbed on its surface a surface modifying agent together an alkali agent. As WO 00/13672 A1 does not contain any details about production of nanoparticles, it is apparent that they
5 are produced by the same procedure as described in WO 98/35666 A1. Accordingly, the same situation as described for WO 98/35666 A1 apply for WO 00/13672 A1.

EP 0 636 363 B1 disclose a rapidly disintegrating
10 tablet dissolving in the mouth at least containing an active ingredient coated with a taste masking coating, a carbohydrate and a binder. In general, such formulations are sensitive against breakage and require a very careful handling, including manufacturing,
15 packaging, transport and administration. Moreover, naproxen is mentioned as active ingredient, but no embodiment is presented.

It is the objective of the present invention to provide
20 a new formulation for Naproxen Sodium having a fast dissolution rate in vitro as well as a fast absorption rate and a decreased fast/fed variability in vivo, which can be produced easily and cheaply.

25 It has been found that a solid Naproxen Sodium formulation having a fast dissolution could be provided when a mixture comprising of Naproxen Sodium and spray-dried mannitol is compressed into tablets. Accordingly, the present invention is directed to a tablet for
30 immediate release of Naproxen Sodium comprising Naproxen Sodium and spray-dried mannitol.

Preferably the spray-dried mannitol used as ingredient for preparation of the tablet has a mass median
35 particle diameter from 75 to 300 microns, a flowability from 25 to 45 degrees, a loose density from 0.35 to 0.75 g/ml and a tapped density from 0.45 to 0.85 g/ml.

Erstelldatum 19.10.2001 14:47
Zuletzt gedruckt 09.11.2001 13:44

I 01/312-Lg

- 3 -

More preferably the spray-dried mannitol used as ingredient for preparation of the tablet has a mass median particle diameter from 75 to 300 microns, a flowability from 25 to 40 degrees, a loose density from 0.40 to 0.60 g/ml and a tapped density from 0.50 to 0.75 g/ml.

Most preferably the spray-dried mannitol used for preparation of the tablet has a mass median particle diameter from 75 to 250 microns, a flowability of about 31 degree, a loose density of about 0.51 g/ml and a tapped density of about 0.60 g/ml. Spray-dried mannitol having said physical properties is marketed by Merck KGaA under the trade name Parateck M200.

"Flowability" as used herein is described by the angle of repose which is measured from a heap carefully built up by dropping the material through a vibrating screen and glass funnel onto a horizontal plate by using a mechanical lever. All values given in the present application for "flowability" are to be understood as measured by the procedure defined in ISO 4324.

"Loose density" as used herein is defined as apparent density of the powder and is calculated as ratio of mass (weight) to volume wherein mass is defined by the specific amount of powder placed in a calibrated cylinder and volume is defined as the volume of this specific calibrated cylinder. All values given in the present application for "loose density" are to be understood as measured by the procedure defined in DIN EN ISO 60.

I 01/312-Lg

- 4 -

- "Tapped density" as used herein is the ratio of mass (weight) to volume obtained by the same procedures as described for "loose density" with the only difference that the volume used for calculation of tapped density is determined after tapped the cylinder for 1250 times. All values given in the present application for "tapped density" are to be understood as measured by the procedure defined in DIN EN ISO 787-11.
- 10 The spray-dried mannitol is present in the tablet of the present invention in an amount from 10 to 90 % by weight, preferably in an amount from 30 to 70 % by weight.
- 15 "Spray-dried mannitol" as used herein is obtained by spray-drying of solutions and/or suspensions of mannitol. To improve process of spray-drying and/or physico-chemical characteristics of the spray-dried mannitol the solutions/suspensions used for its
- 20 producing can also contain a further polyol like sorbitol or lactitol in an amount of 0.1 to 20 % by weight (relating to the total amount of polyol). Accordingly, spray-dried mannitol used for preparation of the tablet of the present invention may also contain
- 25 up to 20% by weight of a further polyol. Preferably the spray-dried mannitol used contain 0.5 to 2.0 % by weight of the polyol, more preferably about 1 % by weight of the polyol. Preferably the polyol which can be further present in the spray-dried mannitol is
- 30 sorbitol.

A process usable for production of spray-dried mannitol as used herein is described in WO 97/39739 A2.

I 01/312-Lg

- 5 -

Advantageously, the tablet of the present invention further contain a lubricant and/or glidant. Lubricants and/or glidants are intended to improve processing of mixture of Naproxen Sodium used for the manufacture of the tablet and, therefore, to achieve a better quality of tablets. Usable lubricants/glidants include, for example, fumed or colloidal silica, stearates (e.g. magnesium stearate, calcium stearate, stearic acid), talc, polyethylene glycol, starch, sodium stearyl fumarate, magnesium lauryl sulphate, sodium lauryl sulphate. Magnesium stearate or sodium stearyl fumarate are preferred. If used, lubricants/glidants are present in a ratio from 0.1 to 10 % by weight.

Moreover, further auxiliary substances such as diluents or disintegrants may be present in the tablet of the present invention.

Usable diluents are, for example, dextrose, dicalcium phosphate, lactose, microcrystalline cellulose, sodium chloride or sucrose.

Usable disintegrants are, for example, starch, cation exchange resin, polyvinylpyrrolidone, modified starch, microcrystalline material (e.g. microcrystalline cellulose), alginic acid, sodium starch glycolate, modified cellulose or gum. Diluents and/or disintegrants may be present in the tablet of invention in an amount from 10 to 90 % by weight and/or from 5 to 90 % by weight, respectively.

The tablet of the present invention can be easily manufactured by mixing its ingredients and compressing the mixture to tablets. Accordingly, the present invention is also directed to a process for the manufacture of the tablet of the present invention which is characterized in that the ingredients of

I 01/312-Lg

- 6 -

present in said tablet are mixed together and compressed to tablets.

Compression of the mixture containing all ingredients
5 of the tablet of the present invention to tablets can
be performed by using conventional tableting machines.
Although parameters of tableting procedure like
compression force also effects dissolution rates of the
tablets, dissolution properties of the tablets are
10 mainly affected by the composition of the mixture used
for compression. Accordingly, the present invention is
also directed to the mixture usable for the manufacture
of the tablet of the present invention, characterized
in that the mixture comprise the ingredients which are
15 present in the tablet.

The following examples are given to illustrate the
present invention. It should be understood, however,
that the invention is not to be limited to the specific
20 conditions or details described in these examples.

I 01/312-Lg

- 7 -

Example 1: Formulation A

Composition of immediate release tablets .

5	Naproxen Sodium	220 mg
	Median Particle Size 91 microns	
	Pardeck M200 (spray-dried Mannitol)	469.5 mg
	PRUV TM (Sodium Stearyl Fumarate)	10.5 mg

10 Blending:

Ingredients were passed through a # 20 mesh to de-lump.
Naproxen Sodium and 50 % of Pardeck M200 were added to
a 2-Qt V-blender and blended for 4 minutes.

15 Rest of the Pardeck M200 was added and blended for an
additional 4 minutes.

Sodium Stearyl Fumarate (previously sieved through a #
40 mesh or finer screen) was added to the blender and
blended for 4 more minutes.

Blend was discharged and stored until tabletted.

20

Tabletting:

Tablets were prepared on a Kilian 28A tablet press.

Tablet press speed was set at 30 rpm.

25 Punches used were 9/16 inches, S.S. concave, bevel
edged.

Compression force was adjusted to attain a tablet
hardness of around 8 KP.

Tablets were collected and stored for testing.

30

I 01/312-Lg

- 8 -

Example 2: Formulation B

Composition

5	Naproxen Sodium	220 mg
	(Median Particle Size 60 microns)	
	Parateck M200 (spray-dried Mannitol)	671 mg
	Mg-Stearate	9 mg

10 Ingredients were mixed and compressed to tablets using the same procedure as described in Example 1.

Example 3: Formulation C

15

Composition

	Naproxen Sodium	220 mg
	Median Particle Size 91 microns	
20	Parateck M200 (spray-dried Mannitol)	469.5 mg
	Mg-Stearate	7 mg
	Cab-O-Sil	3.5 mg

25 Ingredients were mixed and compressed to tablets using the same procedure as described in Example 1.

Comparative Example: Formulation D

30 With the exemption that granular mannitol was used instead of spray-dried mannitol, the same ingredients as used for Formulation B (Example 2) were mixed and compressed to tablets using the same procedure as described in Example 2.

35

Erstelldatum 19.10.2001 14:47
Zuletzt gedruckt 09.11.2001 13:44

I 01/312-Lg

- 9 -

Example 4: In vitro release of Naproxen Sodium

Dissolution test was performed according USP-24
5 apparatus-2 (Paddles) using 900 ml phosphate buffer pH
7.4 at 37°C, speed of rotation was 50 rpm.

Phosphate buffer pH 7.4 (0.1 M) was prepared by
dissolving 2.62 grams of monobasic sodium phosphate and
11.50 grams of anhydrous dibasic sodium phosphate in
10 water to make 1000 ml.

Release rate was determined photometrically at $\lambda = 332$
nm.

Dissolution rates were determined for formulations A,
15 B, C described in Examples 1 to 3, and, for comparison
purposes, for formulation D produced by using granular
mannitol and for two commercially available immediate
release formulations Brand (Aleve®) from Bayer and
Generic from Rite-Aid. Dissolution data obtained are
20 presented as percent dissolved in Table 1 (Mean \pm
standard deviation of at least 3 samples/readings; n.d.
= not determined).

According to the product description, Aleve® contains
25 220 mg of Naproxen Sodium, microcrystalline Cellulose
(MCC), Povidone, Magnesium stearate, Talc and Opadry-
YS-1-4215.

Rite-Aid contains 220 mg of Naproxen Sodium, MCC,
30 Croscarmellose sodium, Povidone, Talc, Colloidal
silicon dioxide, Magnesium stearate and Opadry-YS.
(which contains HPMC, PEG, Polysorbate-80, Titanium
dioxide, F, D & C Blue # 2 Al. lake)

35

Erstelldatum 19.10.2001 14:47
Zuletzt gedruckt 09.11.2001 13:44

I 01/312-Lg

- 10 -

Table 1

% Dissolved (\pm S.D.)						
Time (min)	Formul. A	Formul. B	Formul. C	Formul. D	Aleve [®]	Generic from Rite-Aid
5.0	92.4 (1.0)	n.d.	51.1 (3.4)	n.d.	29.3 (3.0)	24.1 (1.3)
10	92.9 (1.3)	96.0 (0.9)	78.4 (4.6)	60.5 (6.6)	65.8 (3.8)	52.5 (1.7)
20	92.0 (1.0)	n.d.	96.5 (0.7)	n.d.	95.7 (1.0)	87.5 (0.2)
30	91.1 (0.9)	95.0 (0.8)	95.7 (0.8)	90.7 (3.0)	95.2 (0.4)	90.4 (5.1)
60	90.3 (0.9)	94.2 (0.8)	94.7 (0.7)	89.6 (2.8)	93.7 (0.2)	92.3 (1.2)

5

The results clearly shows that the tablets of the present invention have an improved dissolution rate compared to the tablets already on the market. Moreover, the tablet of the present invention containing spray-dried mannitol has also a faster dissolution rate compared to the tablet containing granular mannitol (instead of spray-dried mannitol).

15 Bioavialiability study

Comparative, randomised, single dose, two-way crossover bioavailability study of Naproxen Sodium 220-mg oral tablets was done in 24 healthy Rabbits under fasting

I 01/312-Lg

- 11 -

and fed conditions using formulation A according to Example 1 and Aleve®. Study Drugs (Naproxen Sodium 220-mg tablets) were administered in an oral dose of quarter a-tablet (55 mg) according to a randomisation plan. For all subjects the washout period was 7 days. Twelve (1 - 12) healthy Rabbits were used in the fasted state study, while another twelve (13 - 24) healthy Rabbits were used in the fed state study. Blood samples were taken at timed intervals up to 4 hours after dosing and assayed for Naproxen by high performance liquid chromatography (HPLC). Pharmacokinetic parameters were determined by standard non-compartmental analysis and then subjected to statistical analysis of variance test using Kinetica program.

Pharmakokinetic data obtained are summarized in Table 2.

Table 2

Parameter	fasted state		fed state	
	Formul. A	Comp	Formul. A	Comp
AUC _(0-4 h) [µg/ml h]	88.4	40.6	129.8	32.1
± S.D. [%]	42.3	32.7	71.2	30.8
C _{max} [µg/ml]	32.9	16.7	56.2	15.2
± S.D. [%]	17.5	12.7	28.1	12.2
t _{max} [hours]	1.08	1.50	0.80	0.92
± S.D. [%]	0.88	1.58	1.27	1.20

The data clearly show that time to peak plasma concentration (t_{max}) was shorter and that maximum plasma concentration (C_{max}) was increased for the tablet of the present invention compared to Aleve® of Naproxen

I 01/312-Lg

- 12 -

Sodium, both in fed and in fasted state. Further, the variability of time to peak plasma concentration in fasted state compared to fed state was reduced. Accordingly, the tablet of the present invention leads to a faster onset of action and to a stronger effect, which is especially advantageously when the the tablet is used for the treatment of pain. Moreover, as bioavaiiability (AUC) of the tablet of the present invention is increased the same effect can be obtained with a lower dose of Naproxen Sodium so that the amount of Naproxen Sodium present in the tablet can be reduced.

I 01/312-Lg

- 13 -

PATENT CLAIMS

1. Tablet for immediate release of Naproxen Sodium
comprising Naproxen Sodium and spray-dried
mannitol
2. Tablet according to Claim 1, characterized in that
the spray-dried mannitol used for preparation of
the tablet has a mass median particle diameter
from 75 to 300 microns, a flowability from 25 to
45 degrees, a loose density from 0.35 to 0.75 g/ml
and a tapped density from 0.45 to 0.85 g/ml
3. Tablet according to Claim 1 and/or 2 characterized
in that the spray-dried mannitol used for
preparation of the tablet has a mass median
particle diameter from 75 to 300 microns, a
flowability from 25 to 45 degrees, a loose density
from 0.40 to 0.60 g/ml and a tapped density from
0.50 to 0.75 g/ml
4. Tablet according to one or more of Claims 1 to 3
characterized in that the spray-dried mannitol
used for preparation of the tablet has a mass
median particle diameter from 75 to 250 microns, a
flowability of about 31 degree, a loose density of
about 0.51 g/ml and a tapped density of about
0.60 g/ml
5. Tablet according to one or more of Claims 1 to 4
characterized in that the tablet further contain a
lubricant and/or glidant
6. Tablet according to Claim 5 characterized in that
the lubricant is magnesium stearate and/or sodium

Erstelldatum 19.10.2001 14:47
Zuletzt gedruckt 09.11.2001 13:44

I 01/312-Lg

- 14 -

stearyl fumarate

7. Tablet according to one or more of Claims 1 to 6
characterized in that the spray-dried mannitol is
5 present in the tablet in an amount from 10 to 90 %
by weight
8. Tablet according to Claim 7 characterized in that
the spray-dried mannitol is present in the tablet
10 in an amount from 30 to 70 % by weight
9. Mixture usable for the manufacture of a tablet for
immediate release of Naproxen Sodium characterized
in that the mixture comprise the ingredients as
15 specified in one or more of Claims 1 to 8
10. Process for the manufacture of the tablet
according to one or more of Claims 1 to 8
characterized in that the ingredients present in
20 said tablet, are mixed together and compressed to
tablets

Fetherstonhaugh & Co.
Ottawa, Canada
Patent Agents